Building Your Care Team and First Visit Prep
At a Glance
Preparing for an apparent mineralocorticoid excess visit means building a coordinated team usually led by a kidney specialist and bringing the full genetic report, urinary steroid results, blood-pressure log, medication list, and relevant imaging.
Navigating life with an ultra-rare disease like Apparent Mineralocorticoid Excess (AME) means you are often the most informed member of your local medical community. Finding a single doctor who is an expert in AME is rare; instead, you will build a “circle of care” made up of specialists who each manage one piece of the puzzle [1][2].
Your Care Team Roster
Because AME affects hormones, electrolytes, and the cardiovascular system, a multidisciplinary approach is the standard of care. Your team will likely include:
- Nephrologist (Kidney Specialist): This specialist usually leads the team. They monitor blood pressure, electrolyte levels (like potassium and bicarbonate), and kidney function (eGFR) [3][4]. They also watch for calcium buildup in the kidneys (nephrocalcinosis) [5].
- Endocrinologist (Hormone Specialist): These specialists focus on the 11β-HSD2 enzyme deficiency itself. They help interpret urinary steroid profiles and manage treatments like low-dose dexamethasone while ensuring children are meeting growth milestones [6][4].
- Genetic Counselor: AME is an autosomal recessive condition. A counselor helps explain what having two carrier parents means for siblings and future pregnancies, discusses voluntary testing and privacy, and helps interpret the specific variants [7][8].
- Dietitian: Sodium restriction is a powerful tool in AME management. A dietitian helps translate “low salt” into a practical meal plan and helps avoid dangerous potassium-based salt substitutes [6][4].
- Cardiology and Ophthalmology: Your team may include a heart doctor and an eye doctor to check for signs of strain from high blood pressure [9][3].
Preparing for the First Visit: The Artifact Checklist
In the world of rare diseases, your medical records are essential pieces of evidence that must follow you to every appointment. Bring physical or digital copies of the following:
- The Genetic Report: Bring the full, multi-page report for the HSD11B2 gene. The specific mutation (variant) is more important than a simple “positive” result [4][8].
- Urinary Steroid Profiles: This report shows the cortisol/cortisone metabolite ratio. Ensure the report includes the laboratory’s reference ranges [10][11].
- Growth Charts: For pediatric patients, bring a complete history of height and weight [5][4].
- Blood Pressure Logs: At least two weeks of home blood pressure readings taken with a validated upper-arm cuff under proper resting conditions, noting any symptoms [12][1].
- Current Medications and Action Plan: A complete list of all supplements and medications, plus any existing emergency or illness plans.
- Imaging Reports: Copies of the actual images (on a disc) or the official reports for any renal ultrasounds, ECGs, or echocardiograms [5][9].
Navigating the “Ultra-Rare” Barrier
It is highly likely that your local specialists have limited experience with AME. This is not a reason to lose heart, but it is a reason to be proactive. Experienced specialists will often reach out to national rare-disease networks or specialized pediatric hypertension centers to consult on complex cases [2].
When choosing your team, look for clinicians who are eager to collaborate with global experts and are open to you requesting a second opinion or remote expert review [1]. You are looking for a partner who will learn alongside you to protect long-term health.
Common questions in this guide
Which specialists are usually involved in AME care?
What records should I bring to my first AME appointment?
How should I keep a blood-pressure log for AME?
Why is the exact HSD11B2 variant important in AME?
What if my local clinicians have never treated apparent mineralocorticoid excess?
Are potassium-based salt substitutes safe for someone with AME?
Get notified when new evidence is published on Apparent mineralocorticoid excess.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Facial nerve palsy and hypertension; unusual presentation of apparent mineralocorticoid excess (AME) syndrome in a paediatric patient.
Jawed S, Daffue B, Riordan M, Enright F
BMJ case reports 2026; (19(10)) doi:10.1136/bcr-2026-273050.
PMID: 42843912 - 2
Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.
Yau M, Haider S, Khattab A, et al.
Proceedings of the National Academy of Sciences of the United States of America 2017; (114(52)):E11248-E11256 doi:10.1073/pnas.1716621115.
PMID: 29229831 - 3
Apparent mineralocorticoid excess in Israel: a case series and literature review.
Lebel A, Ben Shalom E, Mokatern R, et al.
European journal of endocrinology 2024; (190(5)):347-353 doi:10.1093/ejendo/lvae049.
PMID: 38652803 - 4
Case report: Clinical characteristics and Genetical analysis of HSD11B2 in three Chinese children with apparent mineralocorticoid excess: a case series.
Ding Y, Cheng M, Cao B, et al.
Frontiers in endocrinology 2024; (15()):1491825 doi:10.3389/fendo.2024.1491825.
PMID: 39931437 - 5
Apparent mineralocorticoid excess with a novel HSD11B2 variant: longitudinal clinical and biochemical follow-Up.
Nalluri BT, Kudugunti N, Sahay RK
JCEM case reports 2026; (4(6)):luag083 doi:10.1210/jcemcr/luag083.
PMID: 42064719 - 6
Apparent mineralocorticoid excess mimicking Bartter syndrome in infancy.
Hatipoğlu S, Yıldırım E, Şalbaş ÖY, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0333.
PMID: 42912472 - 7
Two Qatari siblings with cystic fibrosis and apparent mineralocorticoid excess.
Zahraldin K, Janahi IA, Ben-Omran T, et al.
Annals of thoracic medicine 2015; (10(1)):69-72 doi:10.4103/1817-1737.146892.
PMID: 25593612 - 8
Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Fan P, Lu YT, Yang KQ, et al.
Endocrine 2020; (70(3)):607-615 doi:10.1007/s12020-020-02460-9.
PMID: 32816205 - 9
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Razzaghy-Azar M, Yau M, Khattab A, New MI
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):145-150 doi:10.1016/j.jsbmb.2016.02.014.
PMID: 26892095 - 10
Apparent mineralocorticoid excess.
Funder JW
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):151-153 doi:10.1016/j.jsbmb.2016.03.010.
PMID: 26956190 - 11
Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
Adamidis A, Cantas-Orsdemir S, Tsirka A, et al.
Pediatric endocrinology reviews : PER 2019; (16(3)):335-358 doi:10.17458/per.vol16.2019.act.mineralocorticoid.
PMID: 30888125 - 12
Predictive factors for hypertensive encephalopathy in hospitalized pediatric patients: a retrospective case-control study.
Sengsomwong P, Likasitwattanakul S, Piyaphanee N, et al.
Pediatric nephrology (Berlin, Germany) 2026; (41(10)):3423-3431 doi:10.1007/s00467-026-07300-y.
PMID: 42068363
This page is for informational purposes only and does not constitute medical advice. Your nephrologist and endocrinologist should interpret your AME reports, medications, and blood-pressure plan for your specific situation.